<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03687216</url>
  </required_header>
  <id_info>
    <org_study_id>HGT-EN</org_study_id>
    <nct_id>NCT03687216</nct_id>
  </id_info>
  <brief_title>HVPG-Guided Therapy Versus EVL Plus NSBB in Second Prophylaxis of Esophageal Variceal Bleeding</brief_title>
  <official_title>A Single-center Randomized Controlled Study of Secondary Prophylaxis of Cirrhosis Related Esophagogastric Variceal Hemorrhage Treated With HVPG-guided Therapy or Standard Esophageal Variceal Ligation Plus Beta-blocker</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>West China Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>West China Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A single-center randomized controlled study comparing endoscopic or interventional therapy
      guided by the hepatic venous pressure gradient (HVPG) , to standard endosopic variceal
      ligation plus nonselective beta-blocker therapy (NSBB) in patients with esophageal varices
      due to liver cirrhosis with a history of esophageal variceal hemorrhage.Primary study outcome
      of the study is variceal rebleeding episodes occurring within the first years after
      interventions. Second study outcomes of the study are hepatic encephalopathy occurrence,
      mortality occurrence, liver transplantation or other cirrhosis-related complications.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">September 2019</start_date>
  <completion_date type="Anticipated">December 2020</completion_date>
  <primary_completion_date type="Anticipated">September 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Variceal rebleeding rate</measure>
    <time_frame>One year of follow-up</time_frame>
    <description>The incidence of clinically significant gastrointestinal variceal bleeding</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Hepatic encephalopathy: The incidence of hepatic encephalopathy</measure>
    <time_frame>One year of follow-up</time_frame>
    <description>The incidence of hepatic encephalopathy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ascites: The incidence of ascites detected by ultrasound</measure>
    <time_frame>One year of follow-up</time_frame>
    <description>The incidence of ascites detected by ultrasound</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cirrhotic complications</measure>
    <time_frame>One year of follow-up</time_frame>
    <description>portal vein thrombosis, liver dysfunction, hepatorenal syndrome et al.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Liver transplant-free survivial</measure>
    <time_frame>One year of follow-up</time_frame>
    <description>Time from the procedure to the date of lost-to-follow-up or death or liver transplant</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">160</enrollment>
  <condition>Esophageal Varices in Cirrhosis of the Liver</condition>
  <arm_group>
    <arm_group_label>HVPG group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>HVPG-guided therapy (TIPS or EVL plus NSBB according to HVPG)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Routing group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Routing therapy (EVL plus NSBB)</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>HVPG-guided therapy</intervention_name>
    <description>The baseline HVPG measurement is performed. According to the result, patients with an HVPG over 20 mmHg will be receive transjugular intrahepatic portocaval shunt (TIPS) .
Patients with an HVPG below 20 mmHg will be treated by endoscopic variceal ligation (EVL) plus nonselective beta blocker (NSBB) propranolol until treatment fails.</description>
    <arm_group_label>HVPG group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Routing Therapy</intervention_name>
    <description>Without HVPG measurement, patients receive endoscopic variceal ligation (EVL) plus nonselective beta blocker (NSBB) propranolol.</description>
    <arm_group_label>Routing group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Liver cirrhosis diagnosed by clinical examination, imaging or biopsy;

          -  A previous history of variceal hemorrhage;

          -  Written informed consent.

        Exclusion Criteria:

          -  Previous history of secondary prophylactic treatment;

          -  Contraindications to treatment of endoscopy, surgery and TIPS

          -  Severe cardiac, pulmonary or renal dysfunction;

          -  Lactating or pregnant;

          -  Malignancies;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>West China Hospital</name>
      <address>
        <city>Chengdu</city>
        <state>Sichuan</state>
        <zip>610041</zip>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Li Yang</last_name>
      <phone>+8618980601276</phone>
      <email>yangli_hx@scu.edu.cn</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>March 2019</verification_date>
  <study_first_submitted>September 20, 2018</study_first_submitted>
  <study_first_submitted_qc>September 20, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">September 27, 2018</study_first_posted>
  <last_update_submitted>March 11, 2019</last_update_submitted>
  <last_update_submitted_qc>March 11, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">March 13, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>West China Hospital</investigator_affiliation>
    <investigator_full_name>Li Yang</investigator_full_name>
    <investigator_title>Director of Department of Gastroenterology and Hepatology</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liver Cirrhosis</mesh_term>
    <mesh_term>Esophageal and Gastric Varices</mesh_term>
    <mesh_term>Fibrosis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

